Program
Fluconazole
Also written as “fluconazole”, “Fluconazole 400 mg” and “Diflucan®”.
Its studies are mostly in Meningitis, Cryptococcal · Candidiasis · Candidiasis, Oral · Candidemia · Lymphoma, led by 8 companies.
Drug pageFluconazole: every studyMany companies study it; this page follows only the 37 they lead. All 104 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 260 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Merck | 30 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| AstraZenecaits history only | 20 open or running | phase 1since Mar 20, 2014 | Mar 20, 2014 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jan 13, 2012 | Jan 13, 2012 | none ahead |
| Bayerits history only | 10 open or running | phase 1since Apr 17, 2019 | Apr 17, 2019 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | no phasesince Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Pharmtechnologyits history only | 10 open or running | phase 1since Jul 26, 2019 | Jul 26, 2019 | none ahead |
| Sutphin Drugsits history only | 10 open or running | early phase 1since Jul 31, 2020 | Jul 31, 2020 | none ahead |
Also a collaborator on its studies: Altasciences, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene and Vicuron Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 1999First study: phase 3 study in Candidiasis, OralFirst studyNCT00002446 · 300 enrolled · United States, Barbados
- Nov 2, 1999Phase 2 study in Candidiasis, OralNCT00002399 · 500 enrolled · United States, Argentina, Belgium and more
- Dec 18, 2008Phase 3 study in LeukopeniaNCT00811928 · 252 enrolled
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule
Studies
All 3 Merck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00811928Leukopenia | 3 | Completed | May 2010 | 252 |
| NCT00002446Candidiasis, Oral · United States, Barbados | 3 | Completed | 300 | |
| NCT00002399Candidiasis, Oral · United States, Argentina, Belgium and more | 2 | Completed | 500 |
How it is read
Names in the registry
- “Fluconazole”, 36 entries
- “fluconazole”, 5 entries
- “Fluconazole 400 mg”, 1 entry
- “Diflucan®”, 1 entry
- “Fluconazole 150mg Capsule Localized Originator”, 1 entry
Conditions, from the studies’ own filings
- Meningitis, Cryptococcal, 11 studies
- Candidiasis, 5 studies
- Candidiasis, Oral, 4 studies
- Candidemia, 3 studies
- Lymphoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.